Referencias

1. Devarshi P, Grant R, Ikonte C and Hazels S. Maternal Omega-3 Nutrition, Placental Transfer and Fetal Brain Development in Gestational Diabetes and Preeclampsia. Nutrients
2019; 11(5):E1107.
2. Mayo Foundation for Medical Education and Research. Omega-3 en el pescado: cómo comer pescado ayuda al corazón. Nov, 2019. Consultado en fecha: 15/11/2019.
Disponible en la web: h-ttp-s:/-/www-.mayoclinic-.org-/es-es/diseases-contions/heart-disease/in-depth/omega-3/art-20045614
3. Valenzuela A y Valenzuela R. Ácidos grasos omega-3 en la nutrición, ¿cómo aportarlos? Revista Chilena de Nutrición 2014; 41(2).
4. Chiu Y, Karmon A, Gaskins A, Arvizu M, Williams P, Souter I, et al. Serum omega-3 fatty acids and treatment outcomes among women undergoing assisted reproduction. Human
Reproduction. 2018; 33(1): 156-165.
5. Politano C and López-Berroa J. Omega-3 Fatty Acids and Fecundation, Pregnancy and Breastfeeding. Rev Bras Ginecol Obstet [online] 2020; 42(3):160-164. [Consultado en
fecha 30-06-2020].
6. Kofod R, Stokholm J, Sevelsted A, Chawes B, Bønnelykke K, Barman M, et al. Fish Oil Supplementation in Pregnancy Increases Gestational Age, Size for Gestational Age and
Birth Weight in Infants: A Randomized Controlled Trial. The Journal of Nutrition 2019; 149(4):628-634. h-ttp-s:/-/doi-.org-/10.1093/jn/nxy204
7. Swanson D, Block R and Mousa S. Omega-3 Fatty Acids EPA and DHA: Health Benefits Throughout Life. Advances in Nutrition 2012; 3(1):1-7.
8. Gutiérrez S, Svahn S and Johansson M. Effects of Omega-3 Fatty Acids on Immune Cells. International Journal of Molecular Science 2019; 20, 5028.
9. Behera S. Dietary Fish Oil Concentrates Associated Health Benefits: A Recent Development of Cardiovascular Risk Reduction. Current Pharmaceutical Design 2019.
10. Regitz-Zagrosek V, Roos-Hesselink J. Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, et al. Guía ESC 2018 sobre el tratamiento de las enfermedades
cardiovasculares durante el embarazo. Rev Esp Cardiol 2019; 72(2):161, e1-e65.
11. Shikh E and Makhova A. Long-chain ω-3 polyunsaturated fatty acids in the prevention of diseases in adults and children: a view of the clinical pharmacologist. Vopr Pitan
2019; 88(2):91-100.
12. Gustafsson H, Holton K, Anderson A, Nousen E, Sullivan C, Loftis J, et al. Increased Maternal Prenatal Adiposity, Inflammation, and Lower Omega-3 Fatty Acid Levels
Influence Child Negative Affect.Front Neurosci. 2019; 13:1035.
13. Van Dijk S, Zhou J, Peters T, Buckley M, Sutcliffe B, Oytam Y, et al. Effect of prenatal DHA supplementation on the infant epigenome: results from a randomized controlled
trial. Clinical Epigenetics 2016; 8(114).
14. Organización Mundial de la Salud. Campañas mundiales de salud pública de la OMS. ¿Se pregunta por qué no está contenta tras el nacimiento de su hijo? Nov, 2019.
Consultado en fecha: 15/11/2019. Disponible en la web: h-ttp-s:/-/www-.who-.int-/campaigns/world-health-day/2017/handouts-depression/postnatal/es/
15. Hamazaki, K. Role of Omega-3 Polyunsaturated Fatty Acids in Mental Health-Studies from Japan. Journal of Oleo Science 2019; 68(6):511-515.
16. Sherry C, Oliver J and Marriage B. Docosahexaenoic acid supplementation in lactating women increases breast milk and plasma docosahexaenoic acid concentrations and
alters infant omega 6:3 fatty acid ratio. Prostaglandins, Leukotrienes and Essential Fatty Acids 2015; 95:63-69.
17. Klemens C, Salari K and Mozurkewich E. Assessing Omega-3 Fatty Acid Supplementation During Pregnancy and Lactation to Optimize Maternal Mental Health
and Childhood Cognitive Development. Clin Lipidology 2012;7(1):93-109.
18. Julvez J, Fernández-Barrés S, Gignac F, López-Vicente M, Bustamante M, Garcia-Esteban R, et al. Maternal seafood consumption during pregnancy and child attention
outcomes: a cohort study with gene effect modification by PUFA-related genes. International Journal of Epidemiology. Nov, 2019. h-tt-ps:/-/doi-.org-/10.1093/ije/dyz197
19. Monografía FEMIVITAL cápsulas de gelatina blanda.

Antes

Durante

Después

Este material ha sido aprobado por el Departamento Médico de Exeltis
Centroamérica y República Dominicana.
Material Exclusivo para Profesionales de la Salud.
Para cualquier inquietud, comunicarse al e-mail
direccionmedica.card@exeltis.com y para el reporte de eventos o
reacciones adversas comunicarse al +502 4150-3873 o al email
farmacovigilancia.card@exeltis.com
CARD-SF-FEMI-AVV-09-06-20
Desarrollado por LARS Editores, 2020